Surgical Endoscopy

, Volume 31, Issue 2, pp 538–542 | Cite as

Type 2 diabetes remission following gastric bypass: does diarem stand the test of time?

  • J. Hunter Mehaffey
  • Mathew G. Mullen
  • Rachel L. Mehaffey
  • Florence E. Turrentine
  • Steven K. Malin
  • Jennifer L. Kirby
  • Bruce Schirmer
  • Peter T. Hallowell



Roux-en-Y Gastric Bypass (RYGB) is well known to ameliorate type 2 diabetes mellitus (T2DM), and recent work suggests that the preoperative DiaREM model predicts successful remission up to 1 year post-RYGB. However, no data exist for long-term validity. Therefore, we sought to determine the utility of this score on long-term RYGB effectiveness for T2DM resolution at 2 and 10 years, respectively.


T2DM patients (Age: 48, BMI: 49, HbA1C: 8.1) undergoing RYGB at the University of Virginia between 2004–2006 (n = 42) and 2012–2014 (n = 59) were evaluated prospectively to assess preoperative DiaREM score, defined from insulin use, age, HbA1C, and type of antidiabetic medication. T2DM partial remission status was based on the American Diabetes Association guidelines (HbA1C < 6.5 % and fasting glycemia <125 mg/dL, and no anti-diabetic medications). Chi-square test was used to compare patient’s T2DM status to their DiaREM probability of remission.


Among RYGB patients with 2-year postoperative data, 2 were lost (n = 1 no follow-up and n = 1 died) resulting in 57 patients for analysis. For the 10-year postoperative data, 11 were lost (n = 6 no follow-up and n = 5 died), thereby resulting in only 31 patients for analysis. Patients were distributed by DiaREM score to correlate with the predicted probability of remission as follows: 0–2 (Predicted 94 %, 2-year 100 % p = 0.61, 10-year 100 % p = 0.72), 3–7 (Predicted 76 %, 2-year 94 % p = 0.08, 10-year 83 % p = 0.57), 8–12 (Predicted 36 %, 2-year 47 % p = 0.38, 10-year 43 % p = 0.72), 13–17 (Predicted 22 %, 2-year 20 % p = 0.92, 10-year 33 % p = 0.64), and 18–22 (Predicted 9 %, 2-year 15 % p = 0.40, 10-year 14 % p = 0.64).


Preoperative DiaREM scores are a good tool for predicting both short- and long-term T2DM remissions following RYGB. This study highlights the need to identify strategies that improve T2DM remission in those at highest risk.


Bariatric surgery Diabetes remission DiaREM Obesity 


Compliance with ethical standards


Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number T32HL007849. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


  1. 1.
    Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286(10):1195–1200CrossRefPubMedGoogle Scholar
  2. 2.
    Sturm R (2003) Increases in clinically severe obesity in the United States, 1986–2000. Arch Intern Med 163(18):2146–2148CrossRefPubMedGoogle Scholar
  3. 3.
    Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M (2011) Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378(9793):815–825CrossRefPubMedGoogle Scholar
  4. 4.
    Livingston EH (2010) The incidence of bariatric surgery has plateaued in the US. Am J Surg 200(3):378–385CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Schauer PR, Bhatt DL, Kirwan JP et al (2014) Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N Engl J Med 370(21):2002–2013CrossRefPubMedGoogle Scholar
  6. 6.
    Ricci C, Gaeta M, Rausa E, Macchitella Y, Bonavina L (2014) Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6587 patients. Obes Surg 24(4):522–528CrossRefPubMedGoogle Scholar
  7. 7.
    Sjostrom L, Peltonen M, Jacobson P et al (2014) Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311(22):2297–2304CrossRefPubMedGoogle Scholar
  8. 8.
    Kashyap SR, Bhatt DL, Wolski K et al (2013) Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36(8):2175–2182CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pories WJ, Mehaffey JH, Staton KM (2011) The surgical treatment of type two diabetes mellitus. Surg Clin North Am 91(4):821–836CrossRefPubMedGoogle Scholar
  10. 10.
    Milone M, Di Minno MN, Leongito M et al (2013) Bariatric surgery and diabetes remission: sleeve gastrectomy or mini-gastric bypass? World J Gastroenterol 19(39):6590–6597CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Panunzi S, De Gaetano A, Carnicelli A, Mingrone G (2015) Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg. 261(3):459–467CrossRefPubMedGoogle Scholar
  12. 12.
    Khanna V, Malin SK, Bena J et al (2015) Adults with long-duration type 2 diabetes have blunted glycemic and beta-cell function improvements after bariatric surgery. Obesity (Silver Spring). 23(3):523–526CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Malin SK, Bena J, Abood B et al (2014) Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery. Diabetes Obes Metab 16(12):1230–1238CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hatoum IJ, Blackstone R, Hunter TD, et al (2015) Clinical factors associated with remission of obesity-related comorbidities after bariatric surgery. JAMA Surg, pp 1–8Google Scholar
  15. 15.
    Palmisano S, Silvestri M, Giuricin M, et al (2015) Preoperative predictive factors of successful weight loss and glycaemic control 1 year after gastric bypass for morbid obesity. Obes SurgGoogle Scholar
  16. 16.
    Park JY, Kim YJ (2015) Prediction of diabetes remission in morbidly obese patients after Roux-en-Y gastric bypass. Obes SurgGoogle Scholar
  17. 17.
    Lee WJ, Almulaifi A, Chong K et al (2015) The effect and predictive score of gastric bypass and sleeve gastrectomy on type 2 diabetes mellitus patients with BMI < 30 kg/m(2). Obes Surg 25(10):1772–1778CrossRefPubMedGoogle Scholar
  18. 18.
    Cotillard A, Poitou C, Duchateau-Nguyen G et al (2015) Type 2 diabetes remission after gastric bypass: what is the best prediction tool for clinicians? Obes Surg 25(7):1128–1132CrossRefPubMedGoogle Scholar
  19. 19.
    Still CD, Wood GC, Benotti P et al (2014) Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2(1):38–45CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Aminian A, Brethauer SA, Kashyap SR, Kirwan JP, Schauer PR (2014) DiaRem score: external validation. Lancet Diabetes Endocrinol 2(1):12–13CrossRefPubMedGoogle Scholar
  21. 21.
    Mehaffey JH, LaPar DJ, Clement KC, et al (2015) 10-Year outcomes after Roux-en-Y gastric bypass. Ann SurgGoogle Scholar
  22. 22.
    American Diabetes A (2012) Standards of medical care in diabetes–2012. Diabetes Care 35 (Suppl 1):S11–S63Google Scholar
  23. 23.
    Argyropoulos G (2015) Bariatric surgery: prevalence, predictors, and mechanisms of diabetes remission. Curr Diab Rep 15(4):15CrossRefPubMedGoogle Scholar
  24. 24.
    Ponsky TA, Brody F, Pucci E (2005) Alterations in gastrointestinal physiology after Roux-en-Y gastric bypass. J Am Coll Surg 201(1):125–131CrossRefPubMedGoogle Scholar
  25. 25.
    Pories WJ, Caro JF, Flickinger EG, Meelheim HD, Swanson MS (1987) The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 206(3):316–323CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Harper J, Madan AK, Ternovits CA, Tichansky DS (2007) What happens to patients who do not follow-up after bariatric surgery? Am Surg 73(2):181–184PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • J. Hunter Mehaffey
    • 1
  • Mathew G. Mullen
    • 1
  • Rachel L. Mehaffey
    • 2
  • Florence E. Turrentine
    • 1
  • Steven K. Malin
    • 3
    • 4
  • Jennifer L. Kirby
    • 2
    • 4
  • Bruce Schirmer
    • 1
  • Peter T. Hallowell
    • 1
  1. 1.Department of SurgeryUniversity of VirginiaCharlottesvilleUSA
  2. 2.Department of Internal MedicineUniversity of VirginiaCharlottesvilleUSA
  3. 3.Department of KinesiologyUniversity of VirginiaCharlottesvilleUSA
  4. 4.Division of Endocrinology and MetabolismUniversity of VirginiaCharlottesvilleUSA

Personalised recommendations